CClinicalTrials.gg
Sign In
CompletedNCT05029401Updated Aug 6, 2024

A Study of Oral Ibogaine in Opioid Withdrawal

A Phase 1/2 interventional study of DMX-1002 and Placebo in Opiate Withdrawal Syndrome, sponsored by atai Therapeutics, Inc.. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by atai Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Study DMX-IB 201 is a Phase 1/2a study of ibogaine consisting of an initial single ascending dose escalation stage to determine the maximum tolerated dose (MTD) or treat-to-target dose (TTD) in healthy volunteers, followed by a randomized, double-blind, placebo-controlled proof of concept stage to demonstrate the efficacy, safety and tolerability of the selected dose in opioid-dependent patients who seek medically supervised opioid withdrawal

Read the detailed description

Detailed description restricted as elements of this trial are part of a Phase 1 clinical trial.

02

Conditions studied

  • Opiate Withdrawal Syndrome

Keywords

  • Opioid withdrawal symptoms
  • abrupt opioid discontinuation
  • opioid detoxification
  • opioid use disorder
  • substance use disorder
03

In context

Substance Withdrawal Syndrome

128 studies on the registry are indexed under Substance Withdrawal Syndrome; 8 are open to participants now.

This study's enrollment of 116 is above the median of 53 across 93 interventional studies indexed under Substance Withdrawal Syndrome.

Browse Substance Withdrawal Syndrome studies →

Lead sponsor

atai Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Important Inclusion Criteria for both Stages 1 and 2:

  • Males and females between 18 years and 55 years of age.
  • For Stage 1, healthy volunteers; recreational opioid use is allowed but not required for inclusion in the study.
  • For Stage 2, opioid-dependent subjects (DSM-IV) seeking medically supervised opioid withdrawal and presenting with an OOWS score ≥ 5 on Day 1, prior to dosing.
  • Self-report of at least 1 prior positive hallucinogen drug experience that included a meaningful altered state of consciousness. Hallucinogenic substances can include psilocybin, LSD, MDMA or other classic hallucinogens.
  • Females that are not of child-bearing potential as defined within the protocol.
  • Males who agree to use 1 of the acceptable contraceptive regiments and not to donate sperm from the first study drug administration to at least 90 days after the last drug administration or who are unable to procreate (as defined within the protocol).
  • For Stage 1, negative urine tests for drugs of abuse (opiates, benzodiazepines, amphetamines, cannabinoids, cocaine, barbiturates, and phencyclidine), and CNS (central nervous system) prescription drugs (SSRIs [selective serotonin reuptake inhibitors], SNRIs [serotonin-norepinephrine reuptake inhibitors], mood stabilizers) both at screening and within approximately 7 days prior to dosing, and negative alcohol test.
  • For Stage 2, negative blood and urine tests for methadone, buprenorphine, mitragynine, non-opioid drugs of abuse (benzodiazepines, amphetamines, cannabinoids, cocaine, barbiturates, and phencyclidine), and CNS prescription drugs (SSRIs, SNRIs, mood stabilizers) both at screening and within approximately 7 days prior to dosing, and negative breath alcohol test at Day -1.
  • Negative serology test result for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis C virus antibody at Screening and COVID-19 at Screening and Day -2.
  • Willing to not consume citrus fruits (such as grapefruit, Seville oranges) and/or citrus fruit products throughout the study until Day 6.
  • Willing to refrain from taking any prescription and non-prescription drugs, including herbal and nutritional supplements within 2 weeks prior to Day 1 and throughout the study until Day 6.
  • CYP2D6 genotype that demonstrates gene variants of fast or intermediate metabolism (i.e. not ultra-rapid or poor).

Important Exclusion Criteria for both Stages 1 and 2:

  • Current diagnosis of opioid or other substance dependence (except caffeine) according to DSM-IV or DSM-5 definitions (Stage 1 only).
  • Any history of seizure or convulsion, including febrile convulsion in childhood or as an adult.
  • History of chronic or frequent migraines.
  • Current or recent (≤1 year) history of significant alcohol abuse (>3 units per day on a regular basis)
  • For Stage 1, drug dependency disorder.
  • For Stage 2, polydrug abuse or dependency within the past 3 years other than opioids, caffeine, and/or nicotine.
  • Personal history or presence of primary psychotic disorder (including substance-induced or due to a medical condition), bipolar affective disorder Type I or Type II, or schizophrenia (not including non-psychotic, clinically stable disorders such as depression or anxiety).
  • First or second-degree family history of primary psychotic disorder, bipolar affective disorder Type I or Type II, or schizophrenia.
  • Showing suicidal tendency as per the Columbia Suicide Severity Rating Scale (C-SSRS).
  • Any prior use of ibogaine, noribogaine or other chemically related substances or any allergy or intolerance to excipients in the ibogaine capsules.
  • History or presence of clinically significant cardiovascular disease including angina, myocardial infarction, coronary artery disease, heart failure, arrhythmias, endocarditis, syncope of unknown origin, or any other condition that, in the opinion of the investigator, may be associated with a higher risk of arrhythmias.
  • History or presence at screening (12-lead ECG and 24-hour Holter monitoring) or Day -2 (12-lead ECG) of ECGs that (1) shows QTcF interval duration >420 ms (if QTcF >420 ms prior to dosing on Day 1, subjects need not be excluded provided QTcF was ≤ 420 at Screening and Day -2 and QTcF ≤ 440 on Day 1.), PR interval duration >210 ms, or QRS interval duration >120 ms, obtained as an average from 3 ECG recordings, taken at least 1 minute apart after at least 10 minutes of quiet rest in the supine position; or (2) ECG showing ventricular bigeminy, trigeminy or couplets; or (3) shows, in the opinion of the investigator, any other clinically significant abnormality.
  • History or family history of prolonged QT interval cardiac channelopathy or sudden cardiac death.
  • Orthostatic hypotension or uncontrolled hypertension as characterized by sustained systolic elevation to ≥160 mmHg and/or diastolic elevation to ≥100 mmHg at screening or Day -2.
  • Subjects with an average resting heart rate of \<50 bpm on the ECG at screening.
  • Use of any prescription drugs in the 28 days prior to the first study drug administration, that are known to inhibit or induce CYP2D6 or to cause QT prolongation or, in the opinion of the investigator, would put into question the status of the participant as healthy.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Single dose IMP (DMX-1002)

    Stage 1 (single blind, placebo controlled): initial dose of placebo, followed by treatment at one of 4 ascending dose levels of IMP (3, 6, 9 or 12 mg/kg) Stage 2 (blinded): MTD/TTD established in Stage 1 vs placebo (proof of concept)

    Drug: DMX-1002 · Drug: Placebo

  • Placebo comparator
    Matching Placebo

    Placebo using capsules identical to the IMP (DMX-1002)

    Drug: Placebo

Interventions

  • DrugDMX-1002

    Investigation of the safety, tolerability and pharmacokinetics (PK) in healthy volunteers (Stage 1 - single blind), and the efficacy, safety, tolerability and PK in opioid-dependent patients (Stage 2 - double blind)

    Also known as: Ibogaine Hydrochloride

  • DrugPlacebo

    Matching placebo to the IMP (DMX-1002)

    Also known as: Microcrystalline cellulose

06

What researchers measure

Primary outcomes

  1. Stage 2 - Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) average score from Day 2 to Day 6

    The SOWS-Gossop is a 10-item questionnaire to evaluate opioid withdrawal symptom severity. Each item is scored on a 4-point scale. Higher scores indicate greater severity (total score range 0-40).

    Time frame: Day 2 to Day 6

Secondary outcomes

  1. Stage 2 - Subject completion status at Day 6 (key secondary endpoint)

    Proportion of subjects who received study medication and completed the SOWS-Gossop assessment on Day 6

    Time frame: Day 6

  2. Stage 2 - Objective Opiate Withdrawal Scale of Handelsman (OOWS Handelsman) average score from Day 2 to Day 6

    The OOWS-Handelsman is an interview and observation tool for assessing opioid withdrawal signs and symptoms. It contains 13 physically observable signs, rated present or absent, based on a timed period of observation of the subject by a rater. Higher scores indicate greater severity (total score range 0-13).

    Time frame: Day 2 to Day 6

  3. Stage 2 - Subject completion status at Day 30

    Proportion of subjects who received study medication and completed the SOWS-Gossop assessment on Day 30

    Time frame: Day 30

  4. Stage 2 - Time to drop-out through Day 30

    Time to drop-out

    Time frame: Day 1 to Day 30

  5. Stage 2 - Daily subject-rated Visual Analog Scale for Efficacy (VAS-E) score from Day 2 to Day 6 and at Day 30

    The VAS-E is a scale to quantify the state of craving a subject experienced in the previous 24 hours. The scale size is 100 mm, anchored on the left by "no craving at all" and anchored on the right by "strongest craving ever."

    Time frame: Day 2 to Day 6 and at Day 30

  6. Stage 2 - Clinician-rated daily Clinical Global Impression - Improvement (CGI-I) score from Day 2 to Day 6

    The CGI-I is a 7-point scale that requires the clinician to assess how much the subject's condition has improved or worsened from baseline. The ratings are: 1 - very much improved; 2 - much improved; 3 - minimally improved; 4 - no change; 5 - minimally worse; 6 - much worse; 7 - very much worse.

    Time frame: Day 2 to Day 6

  7. Stage 2 - Hamilton Depression Rating Scale (HAM-D) score at Day 6 and Day 30

    The HAM-D is used to determine a subject's level of depression. The study uses the original 17-item scale. Higer scores indicate greater severity (total score range 0-52).

    Time frame: Day 6 and Day 30

  8. Stage 2 - Proportion of subjects requiring clonidine for relief of withdrawal symptoms up to Day 6

    Proportion of subjects requiring clonidine for relief of withdrawal symptoms

    Time frame: Day 1 to Day 6

Other outcomes

  1. Safety (Stage 1 and Stage 2) - Frequency of treatment-emergent adverse events

    Number of subjects with treatment-emergent adverse events

    Time frame: Day 1 to Day 30

  2. Safety (Stage 1 and Stage 2) - number of subjects with abnormal electrocardiograms (ECG)

    12-Lead ECG including heart rate (HR), QT interval corrected for HR according to Fridericia (QTcF), Individually corrected QTc interval (QTcI), HR-corrected J to T-peak interval (JTpc), PR interval, and QRS interval

    Time frame: Day 1 to Day 30

  3. Safety (Stage 1 and Stage 2) - number of subjects with new magnetic resonance imaging (MRI) findings (in the presence of ataxia greater than 24 hours post-dose)

    MRI of the brain

    Time frame: Day 2

  4. Safety (Stage 1 and Stage 2) - number of subjects with abnormal neurological function

    Neurological function

    Time frame: Day 2 to Day 6

  5. Safety (Stage 1 and Stage 2) - number of subjects with abnormal Scale for the Assessment and Rating of Ataxia (SARA) scores

    The SARA is a tool for assessing ataxia. It includes 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test. Total scores range from 0 (no ataxia) to 40 (most severe ataxia).

    Time frame: Day 2

  6. Safety (Stage 2) - number of subjects with newly emerging suicidal ideation or behavior

    Suicidality is assessed by means of the Columbia Suicide Severity Rating Scale (C-SSRS). It contains 6 "yes" or "no" questions (Q1: wish to be dead; Q2: non-specific suicidal thoughts; Q3-5: more specific suicidal thoughts and intent to act; Q6: suicidal behavior). An answer of "yes" to any of the six questions may indicate a need for referral to a trained mental health professional and an answer of "yes" to questions 4, 5 or 6 indicate high-risk.

    Time frame: Day 6 and Day 30

  7. Pharmacokinetics (Stage 1 and Stage 2) - maximum whole blood and plasma concentrations [Cmax] of ibogaine and noribogaine

    Whole blood and plasma concentrations

    Time frame: 0.5 hours pre-dose up to 120 hours post-dose (Day 6)

  8. Pharmacokinetics (Stage 1 and Stage 2) - time to reach Cmax [Tmax] for ibogaine and noribogaine

    Tmax

    Time frame: 0.5 hours pre-dose up to 120 hours post-dose (Day 6)

  9. Pharmacokinetics (Stage 1 and Stage 2) - area under the concentration-time curve up to the last measurable time point (AUC0-T) for ibogaine and noribogaine

    AUC0-T

    Time frame: 0.5 hours pre-dose up to 120 hours post-dose (Day 6)

  10. Pharmacokinetics (Stage 1 and Stage 2) - apparent elimination half-life (T-half) of ibogaine and noribogaine

    T-half

    Time frame: 0.5 hours pre-dose up to 120 hours post-dose (Day 6)

  11. Pharmacokinetics (Stage 1) - renal clearance (CLr) of ibogaine

    CLr

    Time frame: 0.5 hours pre-dose up to 120 hours post-dose (Day 6)

07

Study locations

2 sites
  • MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence
    Manchester, Greater Mancherster M13 9NQ, United Kingdom
  • Hammersmith Medicines Research (HMR) Limited
    London, NW10 7EW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05029401
Lead sponsor
atai Therapeutics, Inc.
Collaborators
MAC Clinical Research, ERT: Clinical Trial Technology Solutions, Hammersmith Medicines Research
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Apr 1, 2021
Primary completion
Jan 16, 2024
Completion
Jan 16, 2024
Last update
Aug 6, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Substance Withdrawal Syndrome→

Other studies from this sponsor

atai Therapeutics, Inc.

Start the discussion